Table 3.
C-reactive protein (CRP) and procalcitonin (PCT) value in patients of acute Q fever, scrub typhus, and murine typhus with and without delayed responses to doxycycline treatmenta
| Treatment to defervescence ≤3 days | Treatment to defervescence > 3 days | p | ||
|---|---|---|---|---|
| CRP (mg/L) | ||||
| Acute phase (Mean ± SD) | 72.2 ± 58.2 | 102.7 ± 77.1 | 0.041* | |
| > 25 | 75.9% (85/112) | 84.8% (28/33) | 0.276 | |
| > 50 | 61.6% (69/112) | 75.8% (25/33) | 0.135 | |
| > 75 | 40.2% (45/112) | 51.5% (17/33) | 0.247 | |
| > 100 | 26.8% (30/112) | 45.5% (15/33) | 0.042* | |
| > 150 | 8.0% (9/112) | 21.2% (7/33) | 0.053 | |
| > 200 | 2.7% (3/112) | 9.1% (3/33) | 0.131 | |
| Convalescent phaseb (Mean ± SD) | 3.6 ± 13.1 | 19.1 ± 37.4 | 0.049* | |
| > 25 | 3.2% (2/62) | 15.4% (4/26) | 0.060 | |
| > 50 | 1.6% (1/62) | 15.4% (4/26) | 0.025* | |
| > 75 | 1.6% (1/62) | 7.7% (2/26) | 0.207 | |
| > 100 | 0% (0/62) | 3.8% (1/26) | 0.295 | |
| PCT (ng/mL) | ||||
| Acute phase (Mean ± SD) | 0.98 ± 1.40 | 1.39 ± 1.56 | 0.167 | |
| > 0.25 | 70.0% (70/100) | 77.4% (24/31) | 0.423 | |
| > 0.5 | 47.0% (47/100) | 58.1% (18/31) | 0.282 | |
| > 1.0 | 26.0% (26/100) | 48.4% (15/31) | 0.019* | |
| > 1.5 | 20.0% (20/10) | 29.0% (9/31) | 0.290 | |
| > 2.0 | 12.0% (12/100) | 19.4% (6/31) | 0.370 | |
| > 4.0 | 5.0% (5/100) | 9.7% (3/31) | 0.393 | |
| Convalescent phaseb (Mean ± SD) | 0.08 ± 0.26 | 0.39 ± 1.09 | 0.166 | |
| > 0.25 | 6.9% (5/72) | 30.8% (8/26) | 0.005* | |
| > 0.5 | 1.4% (1/72) | 19.2% (5/26) | 0.005* | |
| > 1.0 | 1.4% (1/72) | 3.8% (1/26) | 0.462 | |
| > 1.5 | 1.4% (1/72) | 3.8% (1/26) | 0.462 | |
| > 2.0 | 1.4% (1/72) | 3.8% (1/26) | 0.462 | |
SD standard deviation
*p < 0.05 indicates statistical significance
aPatients who received fluoroquinolones or achieved defervescence before intervention of doxycycline treatment were excluded
bTests for the convalescent phase were performed 11–45 days from the disease onset (average, 20.0 ± 5.6 days; median, 19 days)